Report Overview

The EU Gaucher Disease Treatment Market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period

Gaucher disease is an autosomal recessive inherited metabolism disorder where a type of fat (lipid) called glucocerebroside is unable to degrade. Body synthesis enzyme called glucocerebrosidase, which breakdowns and reprocesses glucocerebroside. Gaucher disease is caused by mutations of a single gene called GBA, which leads to very low levels of glucocerebrosidase enzyme leading to low degradation of glucocerebroside. There are three types of Gaucher disease namely: type 1, type 2, and type 3. Type 1 is the most common type of Gaucher disease while Type 2 and 3 are not as common as type 1



Market Drivers

Approval of novel drugs is expected to boost growth of Gaucher disease treatment market. Europe is expected to be the second largest market for Gaucher disease treatment due to the initiative taken by European organizations to spread awareness about Gaucher disease among the population. European Gaucher Alliance launched Gaucher Awareness Day aiming to spread awareness about this rare disease among the European population which will propel growth